Glenmark Pharmaceuticals' US arm announced the launch of Calcium Gluconate Injection USP in three presentations including single-dose vials and pharmacy bulk package formats, expanding its injectables portfolio in the country. According to the company's exchange filing with BSE, the product is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, of Fresenius Kabi USA. The product has been launched in 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials, along with a 10,000 mg/100 mL pharmacy bulk package. Calcium gluconate is an injectable medication used to increase calcium levels in the body, with calcium playing an important role in maintaining strong bones and heart health, typically administered by healthcare professionals in hospital or clinical settings. Calcium gluconate injection is primarily used for the treatment of acute symptomatic hypocalcemia, making it a critical medication for emergency medical situations.
The Calcium Gluconate Injection market presents a significant opportunity, with annual sales of approximately $69.9 million according to IQVIA sales data for the 12-month period ending June 2026. This launch complements Glenmark's recent FDA approval for Fluticasone Propionate Nasal Spray, which is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase® Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC [NDA 020121]. The combined approvals strengthen Glenmark's position across multiple therapeutic segments in the U.S. market. Marc Kikuchi, President and Business Head, North America, commented on the Calcium Gluconate launch, stating, "The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark's US injectables business and expanding our hospital portfolio."
Glenmark's latest launches come amid strong growth for the drugmaker, which reported a consolidated net profit surge of 930.34% to ₹482.92 crore in the quarter ended June 2026 as against ₹46.87 crore during the previous quarter ended June 2025. Revenue rose by 28.52% to ₹3,931.73 crore in Q1 FY27 over Q1 FY26, demonstrating robust operational performance. However, shares of Glenmark Pharmaceuticals shed 0.54% to currently trade at ₹2,312.35 on the BSE following the announcement, despite the strong quarterly results, reflecting mixed investor sentiment towards the regulatory milestones.
The Calcium Gluconate launch represents Glenmark's disciplined execution of its strategy to build a differentiated and sustainable injectables business that addresses institutional needs and supports greater supply resilience. According to Kikuchi, "It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables business – one that addresses institutional needs, supports greater supply resilience and deepens Glenmark's relevance across the US healthcare system." This expansion builds on Glenmark's recent momentum, where the company recently launched nine products and reported a 19.8% YoY growth in Q1 FY27, excluding out-licensing income. The company's strategic focus on respiratory and injectable therapeutic areas continues to yield high-value regulatory milestones, demonstrating its execution capability in complex generic formulations.
Looking ahead, sustaining this pipeline of niche product launches will be crucial to offset pricing erosion and drive long-term profitability. On July 21, 2026, Glenmark received U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for pediatric patients aged 6 to less than 12 years, broadening its target patient demographic. Additionally, pending regulatory inspections, such as the U.S. FDA clearance for Glenmark's Monroe injectable facility, remain key triggers for the broader portfolio. The company's strategic focus on the respiratory and injectable therapeutic areas continues to yield high-value regulatory milestones, demonstrating its execution capability in complex generic formulations.
